Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Tissue penetration of moxifloxacin into human gallbladder wall in patients with biliary tract infections.

Ober MC, Hoppe-Tichy T, Köninger J, Schunter O, Sonntag HG, Weigand MA, Encke J, Gutt C, Swoboda S.

J Antimicrob Chemother. 2009 Nov;64(5):1091-5. doi: 10.1093/jac/dkp318. Epub 2009 Sep 4.

PMID:
19734170
2.

Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis.

Stass H, Rink AD, Delesen H, Kubitza D, Vestweber KH.

J Antimicrob Chemother. 2006 Sep;58(3):693-6.

PMID:
16895940
3.

Moxifloxacin penetration into human gastrointestinal tissues.

Wirtz M, Kleeff J, Swoboda S, Halaceli I, Geiss HK, Hoppe-Tichy T, Büchler MW, Friess H.

J Antimicrob Chemother. 2004 May;53(5):875-7. Epub 2004 Mar 31.

PMID:
15056642
4.

Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration.

Fuhrmann V, Schenk P, Jaeger W, Ahmed S, Thalhammer F.

J Antimicrob Chemother. 2004 Oct;54(4):780-4. Epub 2004 Sep 3.

PMID:
15347636
5.

Single- and multiple-dose pharmacokinetics of intravenous moxifloxacin in patients with severe hepatic impairment.

Barth J, Jäger D, Mundkowski R, Drewelow B, Welte T, Burkhardt O.

J Antimicrob Chemother. 2008 Sep;62(3):575-8. doi: 10.1093/jac/dkn212. Epub 2008 May 30.

PMID:
18515790
6.

Pharmacokinetics and tissue penetration of moxifloxacin in intervention therapy for intra-abdominal abscess.

Rink AD, Stass H, Delesen H, Kubitza D, Vestweber KH.

Clin Drug Investig. 2008;28(2):71-9.

PMID:
18211115
7.

Pharmacokinetics of intravenously administered moxifloxacin in eye compartments: an experimental study.

Tzepi I, Vergados I, Kanellakopoulou K, Papathanassiou M, Kranidioti H, Tsaganos T, Liarakos V, Giamarellos-Bourboulis EJ, Theodossiadis P.

Int J Antimicrob Agents. 2009 Feb;33(2):160-2. doi: 10.1016/j.ijantimicag.2008.08.010. Epub 2008 Oct 22.

PMID:
18947985
8.

Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose.

Wacke R, Förster S, Adam U, Mundkowski RG, Klar E, Hopt UT, Drewelow B.

J Antimicrob Chemother. 2006 Nov;58(5):994-9. Epub 2006 Sep 6.

PMID:
16956903
9.

Concentration of moxifloxacin in plasma and tonsillar tissue after multiple administration in adult patients.

Esposito S, Noviello S, D'Errico G, Motta G, Passali D, Aimoni C, Pilucchi S, Fallani S, Cassetta MI, Mazzei T, Novelli A.

J Antimicrob Chemother. 2006 Apr;57(4):789-92. Epub 2006 Feb 27. Erratum in: J Antimicrob Chemother. 2006 May;57(5):1022.

PMID:
16504997
10.

Concentrations of moxifloxacin in plasma and urine, and penetration into prostatic fluid and ejaculate, following single oral administration of 400 mg to healthy volunteers.

Wagenlehner FM, Kees F, Weidner W, Wagenlehner C, Naber KG.

Int J Antimicrob Agents. 2008 Jan;31(1):21-6. Epub 2007 Dec 3.

PMID:
18054465
11.

Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty.

Malincarne L, Ghebregzabher M, Moretti MV, Egidi AM, Canovari B, Tavolieri G, Francisci D, Cerulli G, Baldelli F.

J Antimicrob Chemother. 2006 May;57(5):950-4. Epub 2006 Mar 21.

PMID:
16551691
12.

Serum concentrations and pharmacokinetics of moxifloxacin in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass.

Wiesner G, Martin K, Gertler R, Braun SL, Tassani P, Lange R, Gruber M.

Int J Antimicrob Agents. 2013 May;41(5):473-6. doi: 10.1016/j.ijantimicag.2013.01.017. Epub 2013 Mar 6.

PMID:
23481660
13.

Penetration of moxifloxacin into sternal bone of patients undergoing routine cardiopulmonary bypass surgery.

Metallidis S, Charokopos N, Nikolaidis J, Alexiadou E, Lazaraki G, Koumentaki E, Tsona A, Theodoridis G, Nikolaidis P.

Int J Antimicrob Agents. 2006 Nov;28(5):428-32. Epub 2006 Oct 10.

PMID:
17034992
14.

Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect.

Kanellakopoulou K, Pagoulatou A, Stroumpoulis K, Vafiadou M, Kranidioti H, Giamarellou H, Giamarellos-Bourboulis EJ.

J Antimicrob Chemother. 2008 Jun;61(6):1328-31. doi: 10.1093/jac/dkn110. Epub 2008 Mar 18.

PMID:
18353805
15.

Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers.

Burkhardt O, Stass H, Thuss U, Borner K, Welte T.

Clin Pharmacokinet. 2005;44(9):969-76.

PMID:
16122283
16.

Vitreous and aqueous penetration of orally administered moxifloxacin in humans.

Vedantham V, Lalitha P, Velpandian T, Ghose S, Mahalakshmi R, Ramasamy K.

Eye (Lond). 2006 Nov;20(11):1273-8. Epub 2006 Sep 30.

PMID:
16200061
17.

Bile and gallbladder tissue concentrations of moxifloxacin in patients with acute cholecystitis.

Stein GE, Smith CL, Peloquin CA, Mosher B, Dybas L, Kepros JP.

Ann Pharmacother. 2010 Jul-Aug;44(7-8):1346-7. doi: 10.1345/aph.1P100. Epub 2010 Jun 15. No abstract available.

PMID:
20551298
18.

Penetration of moxifloxacin into liver tissue.

Justinger C, Schilling MK, Kees MG, Kauffels A, Hirschmann K, Kopp B, Kees F, Kollmar O.

Int J Antimicrob Agents. 2012 Jun;39(6):505-9. doi: 10.1016/j.ijantimicag.2012.01.022. Epub 2012 Apr 21.

PMID:
22526014
19.

Determination of aqueous and vitreous concentration of moxifloxacin 0.5% after delivery via a dissolvable corneal collagen shield device.

Hariprasad SM, Shah GK, Chi J, Prince RA.

J Cataract Refract Surg. 2005 Nov;31(11):2142-6.

PMID:
16412929
20.

Tissue and serum concentrations of levofloxacin 500 mg administered intravenously or orally for antibiotic prophylaxis in biliary surgery.

Swoboda S, Oberdorfer K, Klee F, Hoppe-Tichy T, von Baum H, Geiss HK.

J Antimicrob Chemother. 2003 Feb;51(2):459-62.

PMID:
12562723

Supplemental Content

Support Center